Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases.
This report describes two patients who developed jaundice within two weeks of receiving an amoxycillin-clavulanate potassium combination. Causes of jaundice, other than drug administration, were excluded. The patients' jaundice and clinical symptoms did not respond to stopping the drug. Ursodeoxycholic acid (750 mg/day) led to a prompt and sustained improvement in their hyperbilirubinaemia and symptoms such as pruritus and fatigue. These cases suggest that ursodeoxycholic acid may be an effective treatment for drug-associated cholestasis.
Katsinelos
P
P
Second Department of Internal Medicine, Aristotelion University, Ippokration Hospital, Thessaloniki, Greece.
Vasiliadis
T
T
Xiarchos
P
P
Patakiouta
F
F
Christodoulou
K
K
Pilpilidis
I
I
Eugenidis
N
N
D000368:Aged; D000369:Aged, 80 and over; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000009:adverse effects*; D001706:Biopsy; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination / Q000009:adverse effects*; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D011379:Prognosis; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid; D019980:Amoxicillin-Potassium Clavulanate Combination